Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE          Parliamentary submission
DATE                2020-08-13
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents

We are writing to you today to alert you to the significant and immediate issues that are impacting Canadians' access to drugs. These challenges have worsened in the wake of COVID-19.

As has been the case with pharmaceuticals and other essential items, our health-care system is facing unprecedented demand for certain medications. This is particularly true for medications used to treat COVID-19 and to manage chronic conditions.

The shortages of these drugs are affecting all sectors of the health-care system. The healthcare system has been stretched to its limits in providing essential services to Canadians. The shortages of these drugs are affecting all sectors of the health-care system. The healthcare system has been stretched to its limits in providing essential services to Canadians.

At the same time, the federal government has been working with industry to address these shortages and to ensure that Canadians have access to the medications they need. However, the situation remains challenging, and we urge you to take further action to address this crisis.

We encourage you to consider the following actions:

1. Implement strategies to increase drug supply through gift programs or other means.
2. Collaborate with international partners to secure additional drug supply.
3. Increase federal investment in research and development of new drugs.

We urge you to act quickly to address this critical issue. The health and well-being of Canadians depend on our ability to provide them with the medications they need.

Sincerely,

[Signature]

[Note: This letter was sent to the federal government and is intended to be a call to action for immediate interventions.]

https://policybase.cma.ca/link/policy14261
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents